Cutaneous infections of mice with vaccinia or cowpox viruses and efficacy of cidofovir

Antiviral Research

Volumn 63, Issue 1, 2004, Pages 33-40

  Quenelle, Debra C ^a   Collins, Deborah J ^a   Kern, Earl R ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Antiviral; Cidofovir; Cutaneous; Mice; Orthopoxvirus

Indexed keywords

CIDOFOVIR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLOGICAL WARFARE; CONTROLLED STUDY; COWPOX VIRUS; EVALUATION; FEMALE; KIDNEY; LUNG; MOUSE; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; SKIN; SKIN BIOPSY; SKIN INFECTION; SPLEEN; VACCINIA; VACCINIA VIRUS;

ADMINISTRATION, CUTANEOUS; ANIMALS; ANTIVIRAL AGENTS; COWPOX; COWPOX VIRUS; CYTOSINE; DISEASE MODELS, ANIMAL; MICE; ORGANOPHOSPHORUS COMPOUNDS; ORTHOPOXVIRUS; PHOSPHONIC ACIDS; VACCINIA; VACCINIA VIRUS;

CANINE DISTEMPER VIRUS; COWPOX VIRUS; ORTHOPOXVIRUS; VACCINIA VIRUS; VARIOLA VIRUS;

EID: 2942657054     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2004.02.003     Document Type: Article

References (36)

1. Bienvenu B., Martinez F., Devergie A., Rybojad M., Rivet J., Bellenger P., Morel P., Gluckman E., Lebbe C. Topical use of cidofovir induced acute renal failure. Transplantation. 73:2002;661-662
2. Boyle J.J., Haff R.F., Stewart R.C. Evaluation of antiviral compounds by suppression of tail lesions in vaccinia-infected mice. Antimicrob. Agents Chemother. 6:1967;536-539
3. Bray M., Martinez M., Smee D.F., Kefauver D., Thompson E., Huggins J.W. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J. Infect. Dis. 181:2000;10-19
4. Buller R.M.L. The BALB/c mouse as a model to study orthopoxviruses. Curr. Top. Microbiol. Immunol. 122:1985;148-153
5. Centers for Disease Control and Prevention, 2003a. Multistate outbreak of monkeypox - Illinois, Indiana, and Wisconsin, 2003. MMWR Morb. Mortal. Wkly. Rep. 52, 537-540.
6. Centers for Disease Control and Prevention, 2003b. Update: multistate outbreak of monkeypox - Illinois, Indiana, Kansas, Missouri, Ohio, and Wisconsin, 2003. MMWR Morbid. Mortal. Wkly. Rep. 52, 616-618.
7. Cundy K.C., Lynch G., Lee W.A. Bioavailability and metabolism of cidofovir following topical administration to rabbits. Antivir. Res. 35:1997;113-122
8. De Clercq E., De Somer P. Effect of interferon, polyacrylic acid, and polymethacrylic acid on tail lesions in mice infected with vaccinia virus. Appl. Microbiol. 16:1968;1314-1319
9. De Clercq E., Luczak M., Shugar D., Torrence P.F., Waters J.A., Witkop B. Effect of cytosine arabinoside, iododeoxyuridine, ethyldeoxyuridine, thiocyanatodeoxyuridine, and ribavirin on tail lesion formation in mice infected with vaccinia virus. Proc. Soc. Exp. Biol. Med. 151:1976;487-490
10. De Clercq E., Holý A., Rosenberg I. Efficacy of phosphonylmethoxyalkyl derivatives of adenine in experimental herpes simplex virus and vaccinia virus infections in vivo. Antimicrob. Agents Chemother. 33:1989;185-191
11. Enserink M. Infectious diseases. US monkeypox outbreak traced to Wisconsin pet dealer. Science. 300:2003;1639
12. Epstein W.L. Molluscum contagiosum. Semin. Dermatology. 11:1992;184-189
13. Fenner F. The pathogenesis of acute exanthems. An interpretation based on experimental investigations with mouse-pox (infectious ectromelia of mice). Lancet. 2:1948;915-920
14. Fields, B.N., Knipe, D.M., Howley, P.M. (Eds.), 1996. Fields Virology, vol. 2. Poxviruses, pp. 2693-2696.
15. Fulginiti V.A., Papier A., Lane J.M., Neff J.M., Henderson D.A. Smallpox vaccination: a review. Part I. Background, vaccination technique, normal vaccination and revaccination, and expected normal reactions. Clin. Infect. Dis. 37:2003a;241-250
16. Fulginiti V.A., Papier A., Lane J.M., Neff J.M., Henderson D.A. Smallpox vaccination: a review. Part II. Adverse events. Clin. Infect. Dis. 37:2003b;251-271
17. Gordon Y.J., Romanowski E., Araullo-Cruz T. Topical HPMPC inhibits adenovirus type 5 in the New Zealand rabbit ocular replication model. Invest. Ophthalmol. Vis. Sci. 35:1994;4135-4143
18. Hillenkamp J., Reinhard T., Ross R.S., Bohringer D., Cartsburg O., Roggendorf M., De Clercq E., Godehardt E., Sundmacher R. Topical treatment of acute adenoviral keratoconjunctivitis with 0.2% cidofovir and 1% cyclosporine. Arch. Ophthalmol. 119:2001;1487-1491
19. Hutin Y.J.F., Williams R.J., Malfait P., Pebody R., Loparev V.N., Ropp S.L., Rodriguez M., Knight J.C., Tshioko F.K., Khan A.S., Szczeniowski M.V., Esposito J.J. Outbreak of human monkeypox, Democratic Republic of Congo, 1996 to 1997. Emerg. Infect. Dis. 7:2001;434-438
20. Kauffman, C.L., Yoon, S.W., 2001. Molluscum contagiosum, eMedicine http://www.emedicine.com/derm/topic270.htm.
21. Kern E.R., Hartline C., Harden E., Keith K., Rodriguez N., Beadle J.R., Hostetler K.Y. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob. Agents Chemother. 46:2002;991-995
22. Lalezari J., Schacker T., Feinberg J., Gathe J., Lee S., Cheung T., Kramer F., Kessler H., Corey L., Drew W.L., Boggs J., McGuire B., Jaffe H.S., Safrin S. A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. J. Infect. Dis. 176:1997;892-898
23. Martinez M.J., Bray M.P., Huggins J.W. A mouse model of aerosol-transmitted orthopoxviral disease. Arch. Pathol. Lab. Med. 124:2000;362-377
24. Maskalyk J. Monkeypox outbreak among pet owners. Can. Med. Assoc. J. 169:2003;44-45
25. Melnick, J.L. (Ed.), 1988. Human Monkeypox, Monographs in Virology, S. Karger AG.
26. Meyer H., Perrichot M., Stemmler M., Emmerich P., Schmitz H., Varaine F., Shungu R., Tshioko F., Formenty P. Outbreaks of disease suspected of being due to human monkeypox virus infection in the Democratic Republic of Congo in 2001. J. Clin. Microbiol. 40:2002;2919-2921
27. Mims C.A. The response of mice to the intravenous injection of cowpox virus. Br. J. Exp. Pathol. 49:1968;24-32
28. Neyts J., De Clercq E. Efficacy of (S)-1-(3-hydroxy-2- phosphonylmethoxypropyl) cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice. J. Med. Virol. 41:1993;242-246
29. Neyts J., De Clercq E. Efficacy of 2-amino-7-(1, 3-dihydroxy-2- propoxymethyl) purine for treatment of vaccinia virus (orthopoxvirus) infections in mice. Antimicrob. Agents Chemother. 45:2001;84-87
30. Neyts, J., Leyssen, P., Verbeken, E., De Clercq, E., 2003. Effect of cidofovir on disseminated/progressive vaccinia in mice. In: Abstract LB-7 of 16th International Conference on Antiviral Research, Savannah, GA, 27 April-1 May.
31. Quenelle D.C., Collins D.J., Kern E.R. Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice. Antimicrob. Agents Chemother. 47:2003;3275-3280
32. Quenelle D.C., Collins D.J., Wan W.B., Beadle J.R., Hostetler K.Y., Kern E.R. Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrob. Agents Chemother. 48:2004;404-412
33. Smee D.F., Bailey K.W., Sidwell R.W. Treatment of cowpox virus respiratory infections in mice with ribavirin as a single agent or followed sequentially by cidofovir. Antivir. Chem. Chemother. 11:2000a;303-309
34. Smee D.F., Bailey K.W., Wong M.H., Sidwell R.W. Intranasal treatment of cowpox virus respiratory infections in mice with cidofovir. Antivir. Res. 47:2000b;171-177
35. Smee, D.F., Bailey, K.W., Sidwell, R.W., 2003. Vaccinia skin lesions in immunosuppressed hairless mice can be treated topically but not parenterally with cidofovir. In: Abstract 129 of 16th International Conference on Antiviral Research, Savannah, GA, 27 April-1 May, 2003. Antivir. Res. 57, A79.
36. Toro J.R., Wood L.V., Patel N.K., Turner M.L. Topical cidofovir: a novel treatment for recalcitrant molluscum contagiosum in children infected with human immunodeficiency virus 1. Arch. Dermatol. 136:2000;983-985